Literature DB >> 15032580

CD40/CD154 interactions at the interface of tolerance and immunity.

Sergio A Quezada1, Lamis Z Jarvinen, Evan F Lind, Randolph J Noelle.   

Abstract

Development of the acquired immune response is dependent on the signaling of CD40 by its ligand, CD154. These molecules govern both the magnitude and quality of humoral- and cell-mediated immunity. A litany of studies have conclusively documented that blockade of this ligand-receptor pair can prevent, and also intervene in, the progression of antibody- and cell-mediated autoimmune diseases, and can instill long-lived allogeneic and xenogeneic graft tolerance. Many effector mechanisms of inflammation are abolished as a result of CD154 blockade, but we are now beginning to understand that CD154 blockade may, in some instances, engender long-lived, antigen-specific tolerance. In the context of transplantation tolerance, we present a hypothesis that alpha CD154 blockade is most effective at inducing long-lived allospecific tolerance if anergy and regulation can be elicited prior to the onslaught of inflammation that is induced by grafting (preemptive tolerance). This facet of alpha CD154-induced tolerance appears to co-opt the normal processes of peripheral tolerance induced by immature DCs and can be exploited to induce long-lived antigen-specific tolerance. The underlying science and the prospects for inducing long-lived antigen-specific tolerance in a model of allograft tolerance through CD154 blockade are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032580     DOI: 10.1146/annurev.immunol.22.012703.104533

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  225 in total

Review 1.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

2.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 3.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

4.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.

Authors:  Ofer Levy; Eugénie E Suter; Richard L Miller; Michael R Wessels
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

Review 5.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

6.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 7.  Janus kinase-3 dependent inflammatory responses in allergic asthma.

Authors:  Rama Malaviya; Debra L Laskin; Ravi Malaviya
Journal:  Int Immunopharmacol       Date:  2010-04-27       Impact factor: 4.932

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

9.  Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism.

Authors:  Kenneth D Bishop; John E Harris; John P Mordes; Dale L Greiner; Aldo A Rossini; Michael P Czech; Nancy E Phillips
Journal:  Cell Immunol       Date:  2009-02-23       Impact factor: 4.868

10.  Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

Authors:  Erin F Gillespie; Nupur Raychaudhuri; Konstantinos I Papageorgiou; Stephen J Atkins; Ying Lu; Laya K Charara; Tünde Mester; Terry J Smith; Raymond S Douglas
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-21       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.